pharma · Migraine · Narcolepsy
H. Lundbeck A/S
H. Lundbeck A/S is a pharma organization headquartered in Valby, CN. Primary therapeutic focus areas include Migraine, Narcolepsy, Schizophrenia, Multiple System Atrophy, Chronic Migrane, Migrane, Medication Overuse Head
Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN HQ
112 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN
- Employees
- 112
- Programs
- 17
- Drugs
- 14
- Patents
- 0
Eptinezumab
Phase 3 · small molecule · Migraine
Eptinezumab for Migraine is a Phase 3 program (small_molecule) at H. Lundbeck A/S with 1 ClinicalTrials.gov record(s).
Internal code 19140B
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- H. Lundbeck A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Migraine
- Status
- completed
- Trials
- 1